Video, Portable and Carrier-Grade IP Phones from Grandstream Now Available for ISTRA by Enreach UCaaS Platform
23.2.2021 11:30:00 EET | Business Wire | Press release
Enreach, the fast-growing European unified communications group, has announced that multiple IP phones from Grandstream have been certified for use on its Unified Communications as a Service (UCaaS) platform, ISTRA by Enreach. Through Enreach for Service Providers, partners and their customers have immediate access to portable and video phones from Grandstream, plus carrier-grade devices designed for mass-deployment.
Bertrand Pourcelot, Managing Director at Enreach for Service Providers, said: “Grandstream’s name has become synonymous with IP phones that combine superior quality and ease-of-use, with options to suit a wide variety of budgets and requirements. Grandstream is a good fit for our portfolio of supporting products for the ISTRA by Enreach UCaaS platform, which is already used by approximately one million users via over 100 service providers in 20-plus countries.”
Grandstream IP phones certified for ISTRA by Enreach
Highlights of the ISTRA-certified range include Grandstream’s GXV3300 series of advanced IP video phones for Android, bringing multimedia AV communications to the desktop, with tablet-style functionality and web access.
For greater mobility in the workplace, the cordless WP810 and WP820 are portable WiFi IP phones, providing robust design and comprehensive features. As well as office or home-working environments, these phones are ideal for retail, logistics, medical, security and other vertical markets where portability is a benefit.
When large volumes of handsets are needed, the GRP2600 series of Carrier-Grade IP phones deliver powerful performance, simplicity of use and easy deployment. As well as supporting basic communications, these devices include next generation features for high-end users.
About ISTRA by Enreach
The ISTRA cloud based UCaaS platform is already deployed by over 100 service providers in more than 20 countries with approximately one million users. It is also the foundation for Enreach’s future-facing platform strategy across the entire group, as part of its ambition to be Europe’s UCaaS leader.
Enreach for Service Providers
Based in Sophia-Antipolis, France, Enreach for Service Providers (previously known as Centile Telecom Applications) is a European leader in the development of Cloud PBX and unified communications platforms for operators and integrators. As well as supporting Enreach for Service Providers own service provider customers, ISTRA by Enreach UCaaS platform is the foundation for Enreach’s future-facing strategy across the entire group, as part of its ambition to be Europe’s UCaaS leader. https://enreach.com/en/for-service-providers
About Enreach
Enreach is the parent company of various labels such as Voiceworks, Swyx, Eazit, i4IP, ipnordic, M Mobility, HeroBase, Network Telecom, Botsquad and masvoz. Enreach provides collaboration technology and telecoms services via their reselling and service providing partners or direct brands that are transformative for SMEs and the people that work with them. All brands contribute to intelligent, integrated IT and communication solutions that ensure optimal communication and workflow between organisations. Enreach’s mission is to give businesses access to the best communication and collaboration tools with an easy, user-centric interface built around their specific needs and systems. The group’s products put powerful features in reach of every business, no matter the industry or size, so their employees can focus on getting amazing things done. Enreach is active in the core markets Germany, the Netherlands, Denmark, UK, Spain and France with activities in 25 countries and 950 employees. https://enreach.com/
About Grandstream
Grandstream Networks, Inc. has been connecting the world since 2002 with SIP Unified Communications products and solutions that allow businesses to be more productive than ever before. Our award-winning solutions serve the small and medium business and enterprises markets and have been recognized throughout the world for their quality, reliability and innovation. Grandstream solutions lower communication costs increase security protection and enhance productivity. Their open standard SIP-based products offer broad interoperability throughout the industry, along with unrivaled features and flexibility. Visit www.grandstream.com for more information or connect with us on Facebook, LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005422/en/
Contact information
Media Contacts
Ambrose Communications
Maxine Ambrose
E mail: maxineambrose@ambrosecomms.com
Tel : + 44 7785 280930
Karine Merouze
International Marcoms Manager
Enreach for Service Providers
E-Mail: karine.merouze@enreach.com
Tel: +33 49 723 1265
For Grandstream
Phil Bowers
marketing@grandstream.com
Tel: 1-617-566-9300
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 08:03:00 EEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
